Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Videndum revenues tumble 25% in H1, shares slide

(Sharecast News) - Videndum tumbled on Wednesday as the manufacturer of hardware and software for the film industry posted a sharp drop in first-half revenue and struck a downbeat tone on the outlook. Revenue tumbled 25% from the first half of 2024 to £115.4m. The company's adjusted operating loss narrowed to £7m from £29.2m a year earlier, while the adjusted loss before tax narrowed to £14.3m from £31.9m.

Executive chairman Stephen Harris said revenues were weaker in the second quarter than the board's expectations at the time of the FY24 results in April.

However, much of the adjusted operating profit impact caused by the revenue shortfall was offset by the restructuring and cost management programmes previously announced.

Harris said that while conditions improved month by month through the first quarter, the ramifications of US trade policies have become clearer in the second quarter.

Videndum said end user demand in the US is running ahead of sales to its distribution channels, as importers have been holding off ordering until the tariff situation becomes clearer. This has led to weaker revenues in the US.

"Ongoing global macro-economic uncertainty, as well as tariff uncertainty, have also had some impact on revenues outside the US," said Harris. "However, end customer sentiment is turning in the independent content creators ("ICC") market and there are increasing signs of pent-up demand in the Cine market. This, in conjunction with the trading environment outlined above, has led to there being a limited amount of inventory in the US.

"The group has put in place stocks of long lead time components to ensure it can respond quickly to any increased demand. Consequently, any uptick in end market demand will feed through into revenue with little delay. Allied to the benefit from the restructuring and cost management programmes previously announced, any improvement in revenue in H2 2025 will drop through to operating profit at a significant rate.

"The ongoing uncertain economic environment and the increased trading volatility due to US tariffs has led to a deterioration in the group's visibility of the potential outcome for FY25."

At 1310 BST, the shares were down 42% at 61.57p.

Broker Shore Capital, which put the stock under review, having previously rated it a 'hold', expects the sharp revenue decline to drive "material downgrades" to consensus.

It noted that management guided to flat revenues for FY25 year-on-year and a low single digit operating margin at the FY24 results on 30 April.

"We believe the company is increasingly unlikely to achieve this given the H1 revenue decline," Shore Capital said.

"£115.4m revenue was delivered in H1, 41% of FY24A. We see no clear signs that market conditions will improve to the extent that H2 revenue will be 46% ahead of H1, as required to meet the previous FY guidance.

"We also believe the prospect of the company delivering an adjusted operating profit this year looks less likely following this morning's update."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.